Biology subjects

Muelken, P.

Publications and source records attributed to Muelken, P..

5 recordsLinked to original sources

bioRxiv2026

The collective effect of non-nicotine constituents on the reinforcing and neuropharmacological effects of comprehensive cigarette smoke and electronic nicotine delivery system (ENDS) aerosol extracts in rats.

Tobacco product extracts containing nicotine and non-nicotine constituents are useful for understanding the collective role of these constituents in tobacco use disorder (TUD). However, few studies have used extracts with both water-soluble and non-water-soluble constituents with accompanying chemical analysis, or compared behavioral and neuropharmacological effects across product types. To address these limitations, we compared the relative abuse liability of cigarette smoke (CS) and electronic nicotine delivery system (ENDS) aerosol (EA) extracts to nicotine alone using intravenous self-administration in rats, and examined effects on nucleus accumbens (NAc) dopamine (DA) release and binding/function at nicotinic acetylcholine receptors (nAChRs) and other addiction-related receptors in vitro. CS extract contained higher levels of several behaviorally active non-nicotine constituents than EA extract. Both extracts produced a downward/leftward shift in the descending limb of the unit dose-response curve relative to nicotine alone, while only CS extract produced greater compensatory increases in responding compared to nicotine alone. Demand intensity (Q0) was lower for CS but not EA extract, relative to nicotine alone, whereas demand elasticity for both extracts was similar to nicotine alone. Stress-induced reinstatement was comparable between CS extract and nicotine alone but attenuated for EA extract. CS extract, but not EA extract, showed greater potency for 4{beta}2 nAChR activation and substantial binding across numerous non-nAChRs (DA, serotonergic, opioid) relative to nicotine alone at a high screening concentration. CS extract, but not nicotine alone, also inhibited cyclooxygenase (COX)-1 and -2 at smoking-relevant concentrations. There was no difference in NAc DA release between formulations. These findings indicate non-nicotine constituents contribute to certain reinforcing and neuropharmacological effects of CS, and to a lesser extent EA. Our finding of COX inhibition by CS extract warrants further investigation as a potential mechanism contributing to the effects of CS and TUD.

pharmacology and toxicology↗

bioRxiv2025

Brain-derived exosome biomarkers of neuroinflammation and neuronal functional iron deficiency in newborns of overweight-obese mothers

BackgroundNon-infectious neuroinflammation (NINI) in early life and neonatal neural iron deficiency (nID) have been proposed to contribute to neurodevelopmental dysfunction and disorders, including autism, through toxic effects on neural cells and impaired molecular signaling. Early detection of NINI and nID may enable interventions to restore neurodevelopmental homeostasis and reduce long-term impact. However, such diagnoses are impossible due to ethical reason to access to the central nervous system (e.g., lumbar puncture) when there is no suspicion of brain infection (e.g., meningitis). MethodsWe refined a methodology to isolate and quantify inflammatory and iron-regulatory proteins in high-quality brain-derived extracellular vesicles (BDEVs) from human umbilical cord blood. A preclinical model was used to validate that BDEV contents reflect the brain microenvironment. We then applied this approach to evaluate biomarkers of NINI and nID in BDEVs isolated from cord plasma of newborns of mothers with obesity, a non-infectious pro-inflammatory gestational condition and a risk factor for nID. FindingsPlasma BDEV analytes correlated more strongly with brain analytes and showed stronger associations among functionally related molecules compared with whole plasma analytes. Maternal obesity induced an anti-inflammatory response in the brain compartment, a pro-inflammatory response in the periphery, and functional nID. InterpretationBDEVs may provide a more sensitive representation of the brain microenvironment than blood-based measures (e.g., plasma), enabling non-invasive, early detection of infants with NINI and neonatal nID. FundingSupported by NIH, the Masonic Institute for Developing Brain, Hennepin Healthcare Research Institute, UnityPoint Health Meriter Foundation, and American Academy of Pediatrics Resident Research Grant. Research in ContextO_ST_ABSEvidence before this studyC_ST_ABSPrevious studies hypothesized that gestational inflammatory environments (e.g., maternal obesity) increase risk of neonatal neural iron deficiency (nID), neuroinflammation, and neurodevelopmental disorders. However, assessing non-infectious neuroinflammation (NINI) in infants from these high-risk groups is not feasible or clinically justifiable using invasive methods (e.g., cerebrospinal fluid collection), and analytes from whole blood or plasma may not accurately reflect brain physiological status. Added value of this studyWe refined a protocol to isolate brain-derived extracellular vesicles (BDEVs) from a small amount of plasma sample (100 {micro}L) and characterized their contents to approximate brain physiology. We demonstrated that BDEVs more accurately reflect brain status compared with whole plasma. In newborns of mothers with obesity during pregnancy, we found evidence of a low-grade peripheral inflammation accompanied by a protective anti-inflammatory response in the brain. Maternal obesity was also found to induce neonatal nID. Implications of all the available evidenceBDEVs can serve as an accurate, non-invasive tool to assess brain condition. In clinical settings, this approach may be used for early diagnosis, monitoring disease progression, and evaluating treatment effects. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=139 SRC="FIGDIR/small/648967v2_ufig1.gif" ALT="Figure 1"> View larger version (52K): org.highwire.dtl.DTLVardef@108caa9org.highwire.dtl.DTLVardef@311ecdorg.highwire.dtl.DTLVardef@dd4086org.highwire.dtl.DTLVardef@1b747ea_HPS_FORMAT_FIGEXP M_FIG C_FIG

physiology↗

bioRxiv2024

The role of β-Nicotyrine in E-Cigarette abuse liability I: Drug Discrimination

Background{beta}-Nicotyrine ({beta}-Nic) is a unique minor alkaloid constituent in electronic nicotine delivery systems (ENDS) that is derived from nicotine (Nic) degradation and can reach 25% of Nic concentrations in ENDS aerosol. {beta}-Nic slows Nic metabolism and prolongs systemic Nic exposure, which may alter the discriminability of Nic. The present study sought to examine {beta}-Nic has interoceptive effects itself, and if it alters the subjective effects ENDS products within a drug-discrimination paradigm. MethodsThe pharmacodynamics of {beta}-Nic were examined in vitro, and a nicotine discrimination paradigm was used to determine if {beta}-Nic (0 - 5.0 mg/kg) shares discriminative stimulus properties with Nic (0.2 mg/kg) in male (n = 13) and female (n = 14) rats after 10- & 60-min {beta}-Nic pretreatment delays. A second group of rats was trained to discriminate {beta}-Nic and Nornicotine (Nornic) from saline to determine if {beta}-Nic alone has interoceptive properties and whether they are similar to Nornic. Results{beta}-Nic had similar binding affinity and efficacy at the 4{beta}2 nicotinic receptor subtype as Nornic, [~]50% of Nic efficacy. However, {beta}-Nic only weakly substituted for Nic during substitution testing in female rats, but not males, whereas Nornic fully substituted for Nic. Combination testing at the 10 and 60-min pretreatment intervals showed that {beta}-Nic dose-dependently increased the duration of nicotines discriminative stimulus effects, especially at the 60-min delay. Drug naive rats could reliably discriminate Nornic, but not {beta}-Nic, from Sal. Conclusion{beta}-Nic increased and prolonged the interoceptive stimulus properties of Nic, suggesting it may alter to the abuse liability of ENDS through its ability to slow Nic metabolism.

pharmacology and toxicology↗

bioRxiv2024

Differential gene expression and chromatin accessibility in the rat medial prefrontal cortex mediating individual variability in vulnerability to opioid use

We characterized gene transcriptional activity in the medial prefrontal cortex of rats associated with individual differences in vulnerability to three distinct phases of opioid use disorder (OUD). Resilient rats showed many more changes in canonical pathway activity than Vulnerable rats in models of both early and advanced OUD, involving passive opioid exposure and opioid self-administration (SA), respectively. The Resilient/Vulnerable phenotype was also associated across phases with functionally specific gene networks, including those mediating epigenetic, neuroimmune, and neuroplasticity function. In contrast, we identified two phase-specific effects. First, differential activity of a myelination-related gene network was associated with Resilience/Vulnerability measured after passive morphine exposure. Second, expression of the calmodulin-inhibitor Pcp4, a gene recently implicated in a rat opioid SA GWAS analysis, was associated with Resilience/Vulnerability measured after SA but not after passive morphine exposure. Thus, we have identified both general and phase-specific transcriptional signatures involved in OUD vulnerability across its trajectory. TeaserAdaptations in the brain transcriptome are associated with resilience and vulnerability to opioid use disorder.

neuroscience↗

bioRxiv2019

Higher anhedonia during withdrawal from initial opioid exposure is protective against subsequent opioid self-administration in rats.

Understanding factors contributing to individual differences in vulnerability to opioid addiction is essential for developing more effective preventions and treatments, yet few reliable behavioral predictors of subsequent opioid self-administration have been identified in rodents. Sensitivity to the acute effects of initial drug exposure predicts later addiction vulnerability in both humans and animals, but the relationship of sensitivity to withdrawal from initial drug exposure and later drug use vulnerability is unclear. The goal of the current study was to evaluate whether the degree of anhedonia experienced during withdrawal from early opioid exposure predicts subsequent vulnerability to opioid addiction. Rats were first tested for withdrawal sensitivity following acute injections of morphine (i.e., "acute dependence"), measured as elevations in intracranial self-stimulation (ICSS) thresholds (anhedonia-like behavior) during naloxone-precipitated and spontaneous withdrawal. Rats were then tested for addiction vulnerability using various measures of i.v. morphine self-administration (MSA) including acquisition, demand, extinction, and reinstatement induced by morphine, stress, and/or drug-associated cues. Greater naloxone-precipitated withdrawal across repeated morphine injections and greater peak spontaneous withdrawal severity following a single morphine injection were associated with lower addiction vulnerability on multiple MSA measures. Withdrawal-induced anhedonia predicted a wider range of MSA measures than did any individual measure of MSA itself. These data suggest that high anhedonia during withdrawal from initial opioid exposure is protective against subsequent opioid addiction vulnerability in rodents, thereby establishing one of the first behavioral measures to predict individual differences in opioid SA. This model promises to be useful for furthering our understanding of behavioral and neurobiological mechanisms underlying vulnerability to opioid addiction.

animal behavior and cognition↗